课题基金 / 基金详情

IC7: a gp130 receptor ligand to treat type 2 diabetes

IC7: a gp130 receptor ligand to treat type 2 diabetes
IC7:治疗 2 型糖尿病的 gp130 受体配体
批准号:
nhmrc : 1042465
负责人:
Prof Mark Febbraio
金额:
$39.93万
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2013
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2013-01-01 至 2015-12-31

项目摘要

项目成果

Prof Mark Febbraio的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Over the past decade work from our group has identified that a group of proteins, termed gp130 receptor cytokines, can lead to improvements in both causes and symptoms of type 2 diabetes in both animals and humans. Unfortunately, due to side effects, clinical trial using analogues of these proteins have failed. We believe we know why this is the case and we now have developed new, improved peptides that should overcome these side effects. We hope that we have created a novel drug that will help treat type 2 diabetes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mapping and defining inter-organ cross talk during exercise
  • 批准号:
    DP220102500
  • 项目类别:
    Discovery Projects
  • 资助金额:
    $42.51万
  • 财政年份:
    2022
  • 负责人:
    Prof Mark Febbraio
  • 依托单位:
Towards a better understanding of the health benefits of physical activity: designing exercise mimetic for the treatment of disease
  • 批准号:
    nhmrc : GNT1116936
  • 项目类别:
    Research Fellowships
  • 资助金额:
    $93.89万
  • 财政年份:
    2017
  • 负责人:
    Prof Mark Febbraio
  • 依托单位:
NAFLD, NASH and Hepatocellular carcinoma: Mechanisms & Potential Treatments
  • 批准号:
    nhmrc : GNT1122227
  • 项目类别:
    Project Grants
  • 资助金额:
    $69.3万
  • 财政年份:
    2017
  • 负责人:
    Prof Mark Febbraio
  • 依托单位:
NAFLD, NASH and Hepatocellular carcinoma: Mechanisms & Potential Treatments
  • 批准号:
    nhmrc : 1122227
  • 项目类别:
    Project Grants
  • 资助金额:
    $47.38万
  • 财政年份:
    2017
  • 负责人:
    Prof Mark Febbraio
  • 依托单位:
国内基金
海外基金
EGR1/gp130轴调节铁代谢在低氧微环境促宫颈癌细胞免疫逃逸中的作用及机制研究
复方清胰汤对肠道菌群、黏膜屏障功能以及对 IL-6/gp130 信 号通路的影响机制研究
IL11-IL11Rα/GP130通过ERK信号通路促进克罗恩病爬行脂肪纤维化形成的机制研究
  • 批准号:
    --
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2022
  • 负责人:
    熊珊珊
  • 依托单位:
GP130信号阻滞CAR-T细胞耗竭的机制研究